Literature DB >> 17181659

Protective effect of adenosine A2A receptor activation in small-for-size liver transplantation.

Li-Ming Tang1, Yan-Peng Wang, Ke Wang, Li-Yong Pu, Feng Zhang, Xiang-Cheng Li, Lian-Bao Kong, Bei-Cheng Sun, Guo-Qiang Li, Xue-Hao Wang.   

Abstract

The aim of the present study was to investigate the potential role of adenosine A(2A) receptor (A(2A)R) activation in small-for-size liver transplantation. A rat orthotopic liver transplantation model was performed by using 40% (range: 36-46%) liver grafts. Recipients were given either saline (control group) or CGS 21680 (2-p-(2-Carboxyethyl)phenethylamino-5'-N-ethylcarboxamidoadenosine hydrochloride, a selective A(2A)R agonist), or CGS 21680+ ZM 241385 (a selective A(2A)R antagonist) immediately after reperfusion for 3 h. Compared with control group, CGS 21680 used at both low dose (0.05 microg/kg/min) and high dose (0.5 microg/kg/min) increased the survival rate from 16.7% (2/12) to 83.3% (10/12) and 66.7% (8/12), respectively. These effects correlated with improved liver function and preserved hepatic architecture. CGS 21680 effectively decreased neutrophil infiltration, suppressed pro-inflammatory (TNF-alpha, IL-1beta and IL-6) expression, promoted expression of antiapoptotic molecules, and inhibited apoptosis. The effects of CGS 21680 were prevented when ZM 241385 was co-administrated. In conclusion, the present study showed that A(2A)R activation alleviated portal hypertension, suppressed inflammatory response, reduced apoptosis, and potentiated the survival of small-for-size liver grafts. Our findings provide the rationale for a novel therapeutic approach using A(2A)R activation to maximize the availability of small-for-size liver grafts.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17181659     DOI: 10.1111/j.1432-2277.2006.00394.x

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  7 in total

Review 1.  Small-for-size syndrome in living-donor liver transplantation using a left lobe graft.

Authors:  Masahiko Taniguchi; Tsuyoshi Shimamura; Satoru Todo; Hiroyuki Furukawa
Journal:  Surg Today       Date:  2014-06-05       Impact factor: 2.549

Review 2.  Purinergic signalling in the liver in health and disease.

Authors:  Geoffrey Burnstock; Byron Vaughn; Simon C Robson
Journal:  Purinergic Signal       Date:  2013-11-24       Impact factor: 3.765

3.  Protective Effects of Adenosine Receptor Agonist in a Cirrhotic Liver Resection Model.

Authors:  Emil Iskandarov; Pramod Kadaba Srinivasan; Wang Xin; Christian Bleilevens; Mamdouh Afify; Astrit Hamza; Lai Wei; Koichiro Hata; Boyukkishi Agayev; Rene Tolba
Journal:  Hepat Mon       Date:  2016-07-24       Impact factor: 0.660

4.  Pharmacological preconditioning with adenosine A1 receptor agonist induces immunosuppression and improves graft survival in novel allogeneic transplantation models.

Authors:  Oshri Naamani; Reut Riff; Cidio Chaimovitz; Julia Mazar; Amos Douvdevani
Journal:  Sci Rep       Date:  2020-03-11       Impact factor: 4.379

Review 5.  Purinergic signaling in liver disease.

Authors:  Byron P Vaughn; Simon C Robson; Maria Serena Longhi
Journal:  Dig Dis       Date:  2014-07-14       Impact factor: 2.404

Review 6.  Ectonucleotidases in solid organ and allogeneic hematopoietic cell transplantation.

Authors:  Petya Chernogorova; Robert Zeiser
Journal:  J Biomed Biotechnol       Date:  2012-10-16

7.  Adenosine A2a Receptor Stimulation Attenuates Ischemia-Reperfusion Injury and Improves Survival in A Porcine Model of DCD Liver Transplantation.

Authors:  Zoltan Czigany; Eve Christiana Craigie; Georg Lurje; Shaowei Song; Kei Yonezawa; Yuzo Yamamoto; Thomas Minor; René Hany Tolba
Journal:  Int J Mol Sci       Date:  2020-09-14       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.